Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Healthcare Marketing Impact Awards
    • Innovators Awards
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women Leaders
    • Digital Health Transformation Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Looking Ahead to 2024
    • - AI and Digital Health
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Opinion
August 20, 2021 01:27 PM

Taking a closer look at dementia in America

Daniel R. George and Dr. Peter J. Whitehouse
  • Tweet
  • Share
  • Share
  • Email
  • More
    Daniel R. George, left, is a medical anthropologist and associate professor at Penn State College of Medicine. Dr. Peter J. Whitehouse is a professor of neurology at Case Western Reserve University and professor of medicine at the University of Toronto. They are co-authors of "American Dementia: Brain Health in an Unhealthy Society."

    In June, the Food and Drug Administration's controversial approval of Biogen's aducanumab (marketed as Aduhelm) for Alzheimer's disease stirred up more questions than answers. The biologic was granted accelerated approval despite major questions about its unclear clinical efficacy, safety/risk profile, and the near-unanimous dissenting opinion of the FDA's own advisory committee. Congressional investigations examining the relationship between the FDA and Biogen—including an inquiry by the inspector general—are underway.

    Meanwhile, healthcare leaders and broader society struggle to reconcile what this situation means. If the approval holds, aducanumab—priced at $56,000/patient per year—will be among the most expensive drugs in history, exceeding what the government annually spends on NASA and the Centers for Disease Control and Prevention combined. Add-on costs associated with imaging, safety monitoring, infusions, and provider time will further compound financial burden. Already, the Veterans Affairs Department, as well as the Cleveland Clinic, Mount Sinai, and Providence health systems, and Excellus Blue Cross and Blue Shield have all declined to offer the drug until results of the ongoing federal investigations are settled. A growing chorus of physicians have publicly stated that they will not prescribe the drug.

    From a health economics perspective, it is not clear that either cost/benefit or cost-utility (quality of life) analyses would demonstrate individual or societal benefit. Expenditures would likely drive up premiums for Medicare Part B and Medicare supplemental policies and increase out-of-pocket expenses for Americans, unless a National Coverage Determination analysis underway precludes Medicare (and then likely private insurers) from payment.

    There are opportunity costs as well. If CMS incurs drug spending at an unprecedented level, this will invariably crowd out other funding priorities including improving acute/chronic care for people with dementia. The Alzheimer's Association has claimed for years that such a drug would save the health system money and stimulate innovative research. Both are unlikely, based on planned "accelerated" submissions from Lilly and other similar drugs.

    Our current predicament is emblematic of what we have come to call our "American dementia"—an undue faith in the capacity of biomedical science and markets to produce a "fix" for Alzheimer's. Despite hundreds of billions of dollars spent on anti-Alzheimer's drugs over the last several decades, there has been little positive impact on the millions of people and caregivers who still cope with those battling age-related cognitive challenges.

    This pharmaceutical, market-oriented approach in pursuit of single-mechanism drugs has narrowed imaginative thinking about how to adapt to the challenges we face as an aging society. One of the more surprising research findings of the last decade is that dementia rates have been in decline in the U.S., Canada and Western Europe. This trend has little to do with biotechnology and ostensibly much to do with mid-20th century public policy that increased education (via the GI Bill and investment in state colleges and universities in the U.S.), expanded healthcare and improved treatment of risk factors that affect the brain (i.e., vascular disease, high cholesterol, hypertension), remarkably successful smoking cessation programs, de-leading gasoline, etc. Collectively, these state actions in service of public health are believed by most experts to have enhanced the brain resilience of those now in their graying years.

    With contemporary uncertainties surrounding drug development foregrounded against the long-term impact of improved social determinants of health on brain aging, it is useful to think about how healthcare organizations might adapt in our current environment. Many institutions must undertake Community Health Needs Assessments, and, invariably, they will document dementia and other age-related chronic conditions as a prevalent issue and thus shoulder responsibility for improving the environments in which aging patients live. Current research suggests 40% of dementia risk may be amenable to prevention/delay, which means an organization's contributions can be significant. Minimizing diabetes, treating hypertension, preventing head injuries, lowering obesity, encouraging smoking cessation and avoidance of excessive alcohol, reducing exposure to air pollution, treating hearing impairment, and fostering opportunities for lifelong learning are all social determinants of brain health that hospitals can impact within their service areas, both clinically and via community outreach.

    From a care perspective, helping seniors age in place may be of particular benefit. This could mean supporting family caregivers and investing in home-based care—specifically in approaches that bring teams (nurses, therapists, social workers) into homes. Given the toxic effects of loneliness on older adults, healthcare systems can support senior centers (or, better yet, "intergenerational centers") and connect patients with opportunities for socialization and meaningful community contributions. Increasingly, healthcare organizations are hosting farmers' markets, community gardens, mobile food markets, and other infrastructure that can integrate elders with their neighbors. Collaborating with national advocacy movements like Dementia Friendly America may be particularly useful for organizations seeking targeted improvements in transportation, nutrition and housing for elders in their service areas.

    Ultimately, while the aducanumab drama plays out on the national (and international) stage, there's still much we can do in our communities—but we must think outside the reductive box of our current American dementia and beyond the false hope peddled by industry and advocacy organizations.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Gray and white arrows
    5 factors impacting next year's hospital financials
    hospital finance numbers
    Labor challenges slowing nonprofit hospital recovery: Fitch
    Most Popular
    1
    CMS may withhold Medicaid funding over redeterminations issues
    2
    Meet the 2023 Most Influential People in Healthcare
    3
    CVS Health unveils 'cost plus' drug pricing model
    4
    Epic CEO Judy Faulkner touts gen AI, clinical research tools
    5
    Physicians leaving private practice hurt patient care: survey
    Sponsored Content
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Healthcare Marketing Impact Awards
        • Innovators Awards
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women Leaders
      • Conferences
        • Digital Health Transformation Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Looking Ahead to 2024
        • - AI and Digital Health
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing